Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
At the core of this is a recovery for its life science unit, which dipped last year as its boom from components for Covid ...
Merck's Q3 revenue rises, led by Keytruda's strong 17% YoY growth. Gardasil demand challenges in China impact sales, with ...
While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...
Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...
In a report released yesterday, Mohit Bansal from Wells Fargo assigned a Hold rating on Merck & Company (MRK – Research Report), ...
Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...
Several African and ex-Soviet countries have expressed interest in buying Russia's vaccine against smallpox and mpox viruses, ...
Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Merck & Company (MRK – Research Report), reducing the price ...